FARA

Vesigen Therapeutics is a biotechnology company focused on developing innovative therapeutic products that address the challenges of targeted intracellular drug delivery. The company's proprietary technology, known as ARMMs (ARRDC1 Mediated Microvesicles), facilitates the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This capability allows for an expanded range of druggable targets and supports the development of new therapies aimed at meeting currently unmet medical needs. By enhancing the delivery mechanisms for next-generation therapeutics, Vesigen Therapeutics aims to contribute significantly to advancements in the field of medicine.